

Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	PFIZER LIMITED*
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Promoter - Wyeth Holdings LLC, USA (Formerly known as Wyeth Holdings Corporation) 235 East 42nd Street New York, New York 10017 United States Members of the promoter group - Pfizer East India B.V. Rivium Westlaan 142, 2909 LD Capelle Aan Den Ijssel, The Netherlands - John Wyeth & Brother Limited, UK Ramsgate Road, Sandwich, Kent, CT13 9NJ United Kingdom - Wyeth LLC, USA 235 East 42nd Street New York, New York 10017 United States - Warner-Lambert Company LLC 235 East 42nd Street New York, New York 10017 U.S.A. - Parke, Davis & Company LLC 235 East 42nd Street New York, New York 10017 U.S.A.

	6. Pharmacia LLC (Formerly known as Pharmacia Corporation) 100, Route 26 North, Peapack New Jersey 07977 U.S.A. Person Acting in Concert 1. Pfizer Inc. 235 East 42nd Street New York, New York 10017		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	- BSE Limited - National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC (*)
Before the acquisition under consideration, holding of :			
a) Shares carrying voting rights			
Promoter			
1. Wyeth Holdings LLC, USA	Nil	Nil	Nil
Members of the promoter group			
1. Pfizer East India B.V.	18186334	60.94	60.94
2. John Wyeth & Brother Limited, UK	Nil	Nil	Nil
3. Wyeth LLC, USA	Nil	Nil	Nil
4. Warner-Lambert Company LLC	1187163	3.98	3.98
5. Parke, Davis & Company LLC	955733	3.20	3.20
6. Pharmacia LLC	783941	2.63	2.63

Person Acting in Concert 1. Pfizer Inc. b) Voting rights (VR) otherwise than by equity shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) d) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	Nil	Nil	Nil
	Nil	Nil	Nil
	Nil	Nil	Nil
	Nil	Nil	Nil
e) Total (a+b+c)	21113171	70.75	70.75
Details of acquisition			
a) Shares carrying voting rights acquired			
Promoter			
1. Wyeth Holdings LLC, USA	1630164	3.56	3.56
Members of the promoter group			
1. Pfizer East India B.V.	Nil	Nil	Nil
2. John Wyeth & Brother Limited, UK	882000	1.93	1.93
3. Wyeth LLC, USA	5617707	12.28	12.28
4. Warner-Lambert Company LLC	Nil	Nil	Nil
5. Parke, Davis & Company LLC	Nil	Nil	Nil
6. Pharmacia LLC	Nil	Nil	Nil

Person Acting in Concert			
1. Pfizer Inc.	Nil	Nil	Nil
b) VRs acquired otherwise than by equity shares	Nil	Nil	Nil
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	Nil	Nil	Nil
d) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	Nil	Nil	Nil
e) Total (a+b+c)	8129871	17.77	17.77
After the acquisition, holding of:			
a) Shares carrying voting rights			
Promoter			
1. Wyeth Holdings LLC, USA	1630164	3.56	3.56
Members of the promoter group			
1. Pfizer East India B.V.	18186334	39.75	39.75
2. John Wyeth & Brother Limited, UK	882000	1.93	1.93
3. Wyeth LLC, USA	5617707	12.28	12.28
4. Warner-Lambert Company LLC	1187163	2.60	2.60
5. Parke, Davis & Company LLC	955733	2.09	2.09
6. Pharmacia LLC	783941	1.71	1.71


Person Acting in Concert 1. Pfizer Inc. b) VRs otherwise than by equity shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition d) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	Nil Nil Nil Nil	Nil Nil Nil Nil	Nil Nil Nil Nil
e) Total (a+b+c)	29243042	63.92	63.92
Mode of acquisition (e.g. open market / public issue / rights issue /preferential allotment / inter-se transfer, etc.)	The allotment of new equity shares has been made pursuant to the Scheme of Amalgamation of Wyeth Limited with Pfizer Limited and their respective shareholders and creditors under sections 391-394 of the Companies Act, 1956 which was sanctioned on October 31, 2014, by the Hon'ble Bombay High Court and as per the following share exchange ratio provided in the Scheme of Amalgamation: <i>7 fully paid up equity shares of Rs. 10 each of Pfizer Limited for every 10 fully paid up equity shares of Rs. 10 each of Wyeth Limited.</i>		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares etc.	Not Applicable		
Date of acquisition of/ date of receipt of intimation of allotment of shares /VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	December 17, 2014		

Equity share capital / total voting capital of the TC before the said acquisition	29,84,14,400
Equity share capital/ total voting capital of the TC after the said acquisition	45,74,77,320
Total diluted share/voting capital of the TC after the said acquisition	45,74,77,320

Note:

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

FOR Wyeth Holdings LLC, USA
(Formerly known as Wyeth Holdings Corporation)



Susan Grant, Vice President & Secretary

Place : Peapack, NJ U.S.A.

Date : December 18, 2014